Enanta Pharmaceuticals, Inc.

NASDAQ:ENTA

Biotechnology

Healthcare
$8.23 -0.67%

-$0.09 today

Market cap
$239.70M
Beta
0.99
P/E (TTM)
-4.3
EPS (TTM)
-$2.90
52W Low $6.44High $17.15

Volume 0.81M

Average 0.17M

ENTA Interest Income

Income earned on cash, deposits, and investments held by the company.

Enanta Pharmaceuticals, Inc.NASDAQ: ENTA

Interest Income · Q2 FY2026 · quarter ended Mar 2026

Interest income declines year over year

Q2 FY2026 interest income of $2.08M fell 9.1% year over year, ahead of the -24.3% change in trailing-twelve-month interest income. Sequentially, it fell 14.0% from the prior quarter. Over 3 fiscal years it compounded at +82.0% a year.

Context

  • Interest income amounted to 14.5% of revenue in FY2025, down 7.3 pp from a year earlier.
  • Interest income increased in 2 of the last 3 fiscal years.

What to watch

Whether quarterly growth of -9.1% holds above the trailing-twelve-month pace of -24.3%.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterMar 2026
$2.08M-14.0% QoQ
Last fiscal yearSep 2025
$9.48M-35.8% YoY
LTMMar 2026
$8.9M-24.3% YoY
Interest Income past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter-9.1%——
1 year-35.8%——
3-year CAGR+82.0%——
5-year CAGR——
10-year CAGR——

Interest Income history

USD · from the income statement

Latest · FY2025
9.48M USD
Year-over-year change
-35.8%
4-year CAGR
+47.2%

Interest Income vs competitors

How ENTA compares with its peers on the latest reported figures

  • ENTA's LTM Mar 2026 interest income of $8.9M is the 3rd highest of the 11 companies compared; the peer median is $4.96M.
  • Its year-over-year change of -24.3% is the 2nd highest of 9, against a peer median of -38.2%.
  • Interest income amounts to 12.9% of revenue for ENTA, versus a peer median of 20.4%.
ENTA Competitors Peer median
Interest Income for ENTA and competitors
Company Period LTM YoY 3-year CAGR% of revenue
AVIRAtea Pharmaceuticals, Inc.LTM Mar 2026$14.02M -40.6%+13.7%—
VYGRVoyager Therapeutics, Inc.LTM Mar 2026$9.24M -44.8%+81.0%25.3%
ENTAEnanta Pharmaceuticals, Inc.LTM Mar 2026$8.9M -24.3%+82.0%12.9%
FHTXFoghorn Therapeutics Inc.LTM Mar 2026$7.8M -35.9%+15.5%27.6%
ASMBAssembly Biosciences, Inc.LTM Mar 2026$7.16M +42.0%+80.4%10.1%
NAUTNautilus Biotechnology, Inc.LTM Mar 2026$7.08M -30.1%+10.6%—
TNYATenaya Therapeutics, Inc.LTM Mar 2026$2.84M -27.6%+11.1%1262.2%
PYXSPyxis Oncology, Inc.LTM Mar 2026$2.83M -58.0%+9.3%20.4%
PRLDPrelude Therapeutics IncorporatedLTM Mar 2026$0 ——0.0%
CRBUCaribou Biosciences, Inc.LTM Mar 2026$0 —+20.3%0.0%
IMRXImmuneering CorporationLTM Mar 2026-$411.45M -18576.2%+44.2%—
Peer median (excluding ENTA) $4.96M-38.2%+15.5%20.4%

Competitors are the stored peer set for ENTA. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Sep 2021
FY2022
Sep 2022
FY2023
Sep 2023
FY2024
Sep 2024
FY2025
Sep 2025
Revenue97.07M86.16M79.2M67.64M65.32M
Cost of Revenue00004.59M
Gross Profit97.07M86.16M79.2M67.64M60.74M
Gross Margin100.0%100.0%100.0%100.0%93.0%
Research & Development174.11M164.52M163.52M131.48M106.74M
Selling, General & Admin32.54M45.48M52.89M57.85M43.93M
Operating Expenses206.65M210M216.41M189.33M146.09M
Depreciation & Amortization3.33M2.97M2.37M2.34M5.09M
EBITDA(104.25M)(119.22M)(123.48M)(104.51M)(70.78M)
EBITDA Margin-107.4%-138.4%-155.9%-154.5%-108.4%
Operating Income(109.57M)(123.84M)(137.21M)(121.69M)(85.35M)
Operating Margin-112.9%-143.7%-173.2%-179.9%-130.7%
Interest Income2.02M1.57M11.36M14.77M9.48M
Interest Expense005.15M10.94M7.68M
Other Income / Expenses1.99M1.66M6.21M3.9M1.8M
Income Before Tax(107.58M)(122.19M)(131M)(117.79M)(83.55M)
Pre-Tax Margin-110.8%-141.8%-165.4%-174.2%-127.9%
Income Tax Expense(28.58M)(433K)2.82M(1.74M)(1.66M)
Net Income(79M)(121.76M)(133.82M)(116.05M)(81.89M)
Net Margin-81.4%-141.3%-169.0%-171.6%-125.4%
EPS (Basic)(3.92)(5.91)(6.38)(5.48)(3.84)
EPS (Diluted)(3.92)(5.91)(6.38)(5.48)(3.84)
Weighted Avg Shares20.17M20.6M20.97M21.16M21.34M
Weighted Avg Shares (Diluted)20.17M20.6M20.97M21.16M21.34M

Enanta Pharmaceuticals, Inc.

NASDAQ:ENTA

Intrinsic Alpha fair value

Locked

Current Price

$8.23

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.